Tags

Type your tag names separated by a space and hit enter

Glutamate release inhibition ineffective in levodopa-induced motor complications.
Mov Disord. 2006 Sep; 21(9):1380-3.MD

Abstract

Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD.

Authors+Show Affiliations

Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

16758479

Citation

Bara-Jimenez, William, et al. "Glutamate Release Inhibition Ineffective in Levodopa-induced Motor Complications." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 21, no. 9, 2006, pp. 1380-3.
Bara-Jimenez W, Dimitrova TD, Sherzai A, et al. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord. 2006;21(9):1380-3.
Bara-Jimenez, W., Dimitrova, T. D., Sherzai, A., Aksu, M., & Chase, T. N. (2006). Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders : Official Journal of the Movement Disorder Society, 21(9), 1380-3.
Bara-Jimenez W, et al. Glutamate Release Inhibition Ineffective in Levodopa-induced Motor Complications. Mov Disord. 2006;21(9):1380-3. PubMed PMID: 16758479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glutamate release inhibition ineffective in levodopa-induced motor complications. AU - Bara-Jimenez,William, AU - Dimitrova,Tzvetelina D, AU - Sherzai,Abdullah, AU - Aksu,Murat, AU - Chase,Thomas N, PY - 2006/6/8/pubmed PY - 2007/2/3/medline PY - 2006/6/8/entrez SP - 1380 EP - 3 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 21 IS - 9 N2 - Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/16758479/Glutamate_release_inhibition_ineffective_in_levodopa_induced_motor_complications_ L2 - https://doi.org/10.1002/mds.20976 DB - PRIME DP - Unbound Medicine ER -